Chugai Pharmaceutical to acquire Renalys Pharma for JPY31bn.

Chugai Pharmaceutical, a research-based pharmaceutical company, agreed to acquire Renalys Pharma, a late-stage clinical biopharmaceutical company, for JPY31bn. "Renalys was built to close Asia's drug lag with a simple promise: patients should not have to wait years for proven therapies. By advancing sparsentan in Japan, we proved that the model works. Partnering with Chugai now scales it—accelerating access across Japan and the region and setting a new standard for how innovative renal medicines reach patients," BT Slingsby, Renalys Representative Director, Chairman & CEO, and Co-Founder.